ArticleDiscover oncology2025
Integrative multi-omic analysis of NLRP3 inflammasome dysregulation and subtyping for personalized treatment in acute myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice.American journal of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a devastating form of blood cancer characterized by uncontrolled growth and impaired maturation of myeloid precursor cells in the bone marrow. Despite advancements in treatment strategies, the prognosis for AML patients remains poor. The NLRP3 inflammasome, a multi-protein complex involved in innate immunity and inflammation, has been implicated in various diseases; however, its role in AML development and progression is not well understood. In this study, we analyzed genomic, bulk-, and single-cell transcriptomic data to assess the contribution of NLRP3 inflammasome genes to AML. Results suggested that 28 NLRP3 inflammasome genes with clinical implications were dysregulated in AML. Notably, we identified seven prognosis-related genes: CASP1, CPTP, MEFV, NFKB2, PANX1, PYCARD, and SIRT2. To further investigate the functional relevance of NLRP3 inflammasome genes, we developed an NLRP3 score (Nscore) based on the expression levels of these seven genes. We identified four dysregulated gene clusters that distinguished high- and low-Nscore groups, enabling the identification of two distinct AML subtypes, with subtype 2 exhibiting worse overall survival than subtype 1. Additionally, using a network-based approach, we identified 62 NLRP3 inflammasome-related genes and constructed a risk score model with COL2A1, ITGB2, and SRC genes, providing a comprehensive assessment of patient risk stratification. We revealed a positive correlation between the Nscore and macrophage M1, suggesting potential drug response mechanisms. Based on the identified AML subtypes and their distinct mutational landscapes, we predicted potential treatment options, with Paclitaxel, Afuresertib, and Mitoxantrone emerging as potential therapeutic agents for the AML subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.